154 related articles for article (PubMed ID: 36114118)
1. Immediate adverse events to intravenous immunoglobulin in pediatric patients with inborn errors of immunity: A longitudinal study with a pre-infusion protocol.
Antunes TS; Melo KM; Valente CFC; Tavares FS
Hematol Transfus Cell Ther; 2023; 45(2):253-258. PubMed ID: 36114118
[TBL] [Abstract][Full Text] [Related]
2. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.
Esmaeilzadeh H; Askarisarvestani A; Hosseini N; Samimi S; Shafiei A; Mahdaviani SA; Eslami N; Chavoshzadeh Z; Fallahi M; Khakbazanfard N; Shabestari MS; Aleyasin S; Nabavizadeh SH; Cheraghi T; Kalantari A; Ahmadiafshar A; Safari M; Eslamian MH; Molatefi R; Shirkani A; Heidarzadeh Arani M; Tavakol M; Bemanian MH; Arshi S; Nabavi M; Shokri S; Shahhosseini B; Mortazavi N; Nakhaei P; Nazari F; Fallahpour M; Ahanchian H; Moazzen N; Khoshkhui M; Motlagh AV; Aghamohammadi A; Abolhassani H; Yazdani R; Rezaei N
Clin Immunol; 2021 Sep; 230():108826. PubMed ID: 34418548
[TBL] [Abstract][Full Text] [Related]
3. Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience.
Kaba S; Keskindemirci G; Aydogmus C; Siraneci R; Erol Cipe F
Eur Ann Allergy Clin Immunol; 2017 Jan; 49(1):11-14. PubMed ID: 28120600
[TBL] [Abstract][Full Text] [Related]
4. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study.
Palabrica FR; Kwong SL; Padua FR
Asia Pac Allergy; 2013 Oct; 3(4):249-56. PubMed ID: 24260730
[TBL] [Abstract][Full Text] [Related]
5. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies.
Perez EE; Hébert J; Ellis AK; Alpan O; Lumry WR; Shapiro R; Suez D; Mandujano JF; Wasserman RL
Front Immunol; 2021; 12():707463. PubMed ID: 34305948
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of intravenous immunoglobulin infusion in Down syndrome regression disorder.
Santoro JD; Jafarpour S; Khoshnood MM; Boyd NK; Vogel BN; Nguyen L; Saucier LE; Partridge R; Tiongson E; Ramos-Platt L; Nagesh D; Ho E; Rosser T; Ahsan N; Mitchell WG; Rafii MS
Am J Med Genet A; 2024 May; 194(5):e63524. PubMed ID: 38169137
[TBL] [Abstract][Full Text] [Related]
8. Surveillance study on the tolerability and safety of Flebogamma
Alsina L; Mohr A; Montañés M; Oliver X; Martín E; Pons J; Drewe E; Papke J; Günther G; Chee R; Gompels M;
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971614
[TBL] [Abstract][Full Text] [Related]
9. Immediate adverse reactions to intravenous immunoglobulin in primary immune deficiencies: a single center experience.
Nain E; Kıykım A; Kasap NA; Barış S; Özen A; Aydıner EK
Turk J Pediatr; 2020; 62(3):379-386. PubMed ID: 32558411
[TBL] [Abstract][Full Text] [Related]
10. [Adverse effects with ambulatory intravenous immunoglobulin administration in adult patients with common variable immunodeficiency].
Rodríguez-Mireles KA; Galguera-Sauceda A; Gaspar-López A; López-Rocha EG; Campos-Romero F; Del Rivero-Hernández L; Amaya-Mejía A; Galindo-Pacheco L; O'Farril-Romanillos P; Segura-Méndez NH
Rev Alerg Mex; 2014; 61(3):131-40. PubMed ID: 25177848
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions.
Singh-Grewal D; Kemp A; Wong M
Arch Dis Child; 2006 Aug; 91(8):651-4. PubMed ID: 16638785
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin G use and pharmacovigilance in a tertiary care children's hospital.
Yori S; Belleri F; Testard J; Fierro Vidal Á; Rousseau M
Arch Argent Pediatr; 2021 Jun; 119(3):192-197. PubMed ID: 34033419
[TBL] [Abstract][Full Text] [Related]
13. Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.
Ibis IBP; Erdur B; Erdem SB; Karaman S; Gulez N; Genel F
Allergol Immunopathol (Madr); 2020; 48(6):738-744. PubMed ID: 32703652
[TBL] [Abstract][Full Text] [Related]
14. One-year intravenous immunoglobulin replacement therapy: efficacy in reducing hospital admissions in pediatric patients with Inborn Errors of Immunity.
Melo KM; Alves LM; Valente CFC; Tavares FS
J Pediatr (Rio J); 2022; 98(2):190-195. PubMed ID: 34273274
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
16. Acute and long-term immune responses to SARS-CoV-2 infection in unvaccinated children and young adults with inborn errors of immunity.
García-García A; Fortuny C; Fumadó V; Jordan I; Ruiz-López L; González-Navarro EA; Egri N; Esteve-Solé A; Luo Y; Vlagea A; Cabedo MM; Launes C; Soler A; Codina A; Juan M; Pascal M; Deyà-Martínez A; Alsina L
Front Immunol; 2023; 14():1084630. PubMed ID: 36742319
[TBL] [Abstract][Full Text] [Related]
17. Adverse Reactions to Intravenous Immunoglobulins - Our Experience.
Kareva L; Mironska K; Stavric K; Hasani A
Open Access Maced J Med Sci; 2018 Dec; 6(12):2359-2362. PubMed ID: 30607191
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J
Front Immunol; 2019; 10():40. PubMed ID: 30778345
[No Abstract] [Full Text] [Related]
19. [Adverse events in 1395 infusions with different intravenous gammaglobulin products].
Malbrán A; Larrauri B; Juri MC; Fernández Romero DS
Medicina (B Aires); 2013; 73(5):433-7. PubMed ID: 24152399
[TBL] [Abstract][Full Text] [Related]
20. BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children.
Kriván G; Borte M; Soler-Palacin P; Church JA; Csurke I; Harris JB; Lieberman JA; Melamed IR; Moy JN; Simon R; Aigner S; Lentze S; Staiger C
J Clin Immunol; 2023 Apr; 43(3):557-567. PubMed ID: 36383294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
